Global mRNA Vaccine Market Analysis – 2023-2033

According to the Market Statsville Group (MSG), the Global mRNA Vaccine Market size is estimated to grow from USD 41,187.01 million in 2023 to USD 48,272.23 million by 2033, at a CAGR of 1.6% from 2023 to 2033.

As part of a therapeutic option, the mRNA vaccine is a nucleic acid-based vaccination that contains messenger RNAs that allow the patient's cells to create proteins. These vaccines have self-adjuvant characteristics. To elicit a strong immune response, the mRNA vaccination uses the host cell machinery to translate the mRNA into its appropriate antigen. The use of mRNA vaccines is to prevents the possibility of infectious particles that are being produced in the body. mRNA vaccines can be utilized for a variety of purposes, including preventative and therapeutic vaccines, protein replacement, cancer immunotherapy, allergy tolerization, and many others.

As mRNA vaccines can be produced rapidly and are inexpensive, their demand on the market is increasing. Increasing research initiatives on the development of mRNA vaccines for numerous chronic diseases, including COVID-19 virus, have propelled the market growth. Furthermore, such vaccines have fewer negative effects on the body, effectively alleviating disease conditions.

Moreover, the market is expected to drive during the forecast period due to the usage of advanced medical technologies, greater quality of services, efficiency, and unique pharmaceutical innovations. However, the mRNA vaccine market lacks flexibility and durability. This may hinder market growth in the short term. The cost-effective production procedures and a long-term need for mRNA vaccines will drive growth over the forecasting period in all around the globe.

Market Segmental Analysis, 2023-2033

Based on end user, the market is divided into research institutes and hospitals and clinics. The hospitals and clinics segment accounted for the largest market share in 2023. The increased use of vaccines and therapies to treat a wide range of chronic diseases is propelling the personalized pharmaceuticals market over the forecasting period. The growing number of patients visiting hospitals and clinics is also driving the industry. Furthermore, an increase in the number of patients suffering from cancer, influenza, infectious disorders, and respiratory illnesses is likely to fuel market expansion.

Based on the regions, the global mRNA vaccine market has been segmented across Europe, North America, the Middle East & Africa, Asia-Pacific, and South America. North America accounted for the largest market share in 2023. The North American market for mRNA vaccines is expected to dominate the global market due to an increase in research in the healthcare sector. A rise in the level of living, as well as new medical technologies, are some of the factors driving the industry in the United States. As one of the most industrialized countries in the world, the United States serves as a center for complicated medical treatments for many individuals all over the world.  The mRNA vaccine industry in the United States has been significantly strong for a few years due to rising consumer demand in the healthcare domain, and it is expected to develop even more throughout the projected period.

Key Market Players

The Major key players in the global mRNA vaccine market are: 

• BioNTech AG
• Sangamo Therapeutics, Inc
• Arcturus Therapeutics
• Ionis Pharmaceuticals, Inc
• IN-CELL-ART
• Alnylam Pharmaceuticals
• SCM Life Sciences (Argos Therapeutics, Inc.)
• Ethris GMBH
• Sarepta Therapeutics
• GSK Plc
• Tiba Biotech
• Sanofi AG
• Etherna Immunotherapies
• Nutcracker
• Curevac AG
• Moderna Therapeutics

(Note: we include the maximum-to-maximum top/key companies in the final report with the recent development, partnership, and acquisition of the companies.)

Recent Development 

• In July 2021, Eurofins Agroscience Services (EAS) announced the partnership with the EAS Hercules laboratory in North America. This helped the company to expand its global presence.
• In July 2021, ICON Plc acquired PRA Health Sciences. By generating much-needed medications and medical devices, the integrated company exploited its expanded functionalities to alter clinical trials and expedite the success of biopharma clients.

Report Scope of the Global mRNA Vaccine Market 

This market research study categorizes the mRNA vaccine market-based on type, application, and end user area at the regional and global levels.

By Type Outlook (Sales, USD Million, 2019-2033)

• Self-Amplifying mRNA Vaccines (SAM)
• Conventional Non-Amplifying mRNA Vaccines

By Application Outlook (Sales, USD Million, 2019-2033)

• Cancer Immunotherapy
• Allergy Tolerization
• Therapeutic Vaccines
• Protein Replacement
• Others

By End User Outlook (Sales, USD Million, 2019-2033)

• Research Institutes
• Hospitals and clinics

By Region Outlook (Sales, USD Million, 2019-2033)

• North America 
  • US
  • Canada
  • Mexico
• Europe 
  • Germany
  • Italy
  • France
  • UK
  • Spain
  • Poland
  • Russia
  • The Netherlands
  • Norway
  • Czech Republic
  • Rest of Europe
• Asia Pacific 
  • China
  • Japan
  • India
  • South Korea
  • Indonesia
  • Malaysia
  • Thailand
  • Singapore
  • Australia & New Zealand
  • Rest of Asia Pacific
  • South America
  • Brazil
  • Argentina
  • Colombia
  • Rest of South America
• The Middle East & Africa
  • Saudi Arabia
  • UAE
  • South Africa
  • Northern Africa
  • Rest of MEA